Audioboom Group 235p £38.5m (BOOM.L)
The global podcast company provides this flash view of the Group's performance in August 2024, with monthly revenue expected to continue to grow in the remaining months of the year. Revenue increased 35% to US$6.0m (Aug 2023: US$4.4m), adjusted EBITDA of US$0.3m (Aug 2023: loss US$0.1m) and global downloads of 103m - up from the Q2 2024 monthly average of 95m, highlighting the return to growth of the Audioboom Creator Network following Apple's iOS17 update in late 2023 which impacted the measurement of downloads across the industry .
Blackbird 5.25p £20.3m (BIRD.L)
The technology licensor, developer and seller of the market-leading cloud video editing platform, Blackbird, and developer of the online multiplayer video editor, elevate.io announces its interim results for the six months ended 30 June 2024. Revenues decreased to £692k (30 June 2023: £985k), EBITDA loss decreased to £1.41m (30 June 2023: £1.52m) and cash and short term investments of £5.62m (30 June 2023: £8.18m). There will be a shift towards increased marketing activity to drive user adoption prior to a payment gateway in Q1 2025. The Company is well positioned to execute its strategy with a world-class team in place and funds of c.£5.6m at 30 June 2024.
Coro Energy * 0.0825p £2.4m (CORO.L)
The South East Asian energy company with a natural gas and clean energy portfolio announces its final results for the year ended 31 December 2023. Revenue increased to US$235k (2022: US$51k), loss before tax decreased to US$5.05m (2022: US$8.19m) and cash and cash equivalents US$1.1m (2022: US$166k). Further highlights include: Restructuring of the Philippines renewables business increasing Coro's entitlement to future dividends to 88%, disposal of Italian portfolio to Zodiac Energy plc and First Wind Energy Service Contract (WESC) awarded in the Philippines.
Eleco 136p £112.0m (ELCO.L)
The software provider for the built environment announces its interim results for the six months ended 30 June 2024. Total revenue increased 21% to £16.3m (H1 2023: £13.5m), profit before tax increased 23% to £1.6m (H1 2023: £1.3m) and cash as at 30 June 2024 was £12.0m (30 June 2023: £9.4m). The built environment market is buoyant and continues to present a significant opportunity for Eleco, due to the increasing adoption of technology to solve the challenges faced by construction and property management companies. As Eleco expands its presence in its core geographical markets, it continues to strengthen its reputation as a trusted provider of best-of-breed solutions.
Futura Medical 40.8p £123.2m (FUM.L)
The consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products announces its unaudited interim results for the six months ended 30 June 2024. Revenue increased over 300% to £7.0m (H1 2023: £1.7m) generated from £3.8m of product sales (H1 2023: £1.7m) and £3.2m following the recognition of US commercial milestone received in 2023, profit after tax was £1.0m (H1 2023: loss of £2.0m) and cash position at 30 June 2024 of £3.9m (H1 2023: £7.8m). The Board is confident in the outlook for the remainder of the year and confirms that both revenue and profit will significantly exceed market expectations for the full year.
Global Connectivity * 1.725p £6.2m (AQSE: GCON)
Through its investment in Rural Broadband Solutions Holdings Limited (RBSHL) and thereby an indirect investor in Voneus Limited (Voneus), a provider of Broadband Services to rural areas of the UK today announces its unaudited half year results for the six months ended 30 June 2024. Net assets increased by £9.4m to £17.2m (31 Dec 2023: £7.8m). As at 30 June 2024, cash increased to £318k (30 June 2023: £33k) with additional funding due by 31 December 2024. As at 30 June 2024 the net asset value per share is 4.75p (31 Dec 2023: 2.16p). The increase in pace of investment into Voneus has meant that business progress has exceeded GCON’s expectations, with homes passed, including work in progress, exceeding 100,000.
Hvivo 29.75p £202.4m (HVO.L)
The contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials announces its unaudited interim results for the six-month period ended 30 June 2024. Revenue increased 31% to £35.6m (H1 2023: £27.3m), EBITDA increased 67.6% to £8.7m (H1 2023: £5.2m) and cash of £37.1m as at 30 June 2024 (H1 2023: £31.3m). Full year revenue guidance of £62m reaffirmed with full year EBITDA margins anticipated to be at the upper end of market expectations..
Newmark Security 97.5p £9.1m (NWT.L)
The provider of electronic, software, and physical security systems and installations announces its audited results for the year ended 30 April 2024. Revenue up 10% to £22.3m (2023: £20.3m), EBITDA up 50% to £2.2m (2023: £1.5m) and cash at bank of £1.1m at year end (2023: £0.6m). The Board is cautiously optimistic on the outlook for the full year, building on partnerships signed in 2024. Commenced implementation of new five-year business plan to drive further growth in recurring revenue streams and service offering.
Tissue Regenix Group 66p £47.0m (TRX.L)
The regenerative medical devices company reports its unaudited interim results for the six months ended 30 June 2024. Group revenues increased by 16% to US$16.4m (H1 2023: US$14.1m), profit before taxation of US$0.1m (H1 2023: US$0.9m loss) and cash position of US$3.5m (H1 2023: US$4.1m). The performance of the group over the last three years gives them confidence in moving forward, and the Board will continue to explore additional opportunities for expansion in each of their growth pillars.
TPXimpact Holdings 41.5p £37.9m (TPX.L)
The technology-enabled services company focused on people-powered digital transformation provides a trading update in advance of the Company's Annual General Meeting (AGM) on 26 September 2024. The Company now expects to report first half revenues down c.8-10% against last year, with a return to growth in the second half of the year. Continuing their three-year strategy to simplify the business, and recognising the challenges of the current market environment, the Company has taken action to further improve its operational efficiency, primarily in relation to staff costs. On an annualised basis, these actions are expected to save well over £3m of cost, with an in-year FY25 benefit of around half this amount. Given these factors, the Company now expects to report flat revenue growth for FY25 (FY24 revenue: £84.3m).
.
Status of this Note and Disclaimer
This document has been provided as a general market commentary and is issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as investment advice; a recommendation; an offer to sell; nor solicitation of any offer to buy any security or other financial instrument. Nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. The information has been provided without taking into account the investment objective, financial situation or needs of any particular person. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
As market commentary, this document is not investment research or a research recommendation for regulatory purposes as it does not constitute substantive research or analysis. It is not subject to any prohibition on dealing ahead of the dissemination of investment research although Hybridan LLP maintains related internal systems and controls in connection with such dealing.
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result, both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
This document is not intended to be an invitation or inducement to engage in investment activity. In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are categorised by Hybridan LLP as either a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the avoidance of doubt, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. The information may contain projections or other forward-looking statements regarding future events, targets or expectations. There is no assurance that such events or expectations will be achieved, and actual results may be significantly different from that shown here. The information is based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein.
References to specific securities, asset classes and financial markets are for illustrative purposes only. Past performance is no guarantee of future results. Information and opinions presented have been obtained or derived from sources which Hybridan LLP reasonably believed to be reliable however no representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any losses arising in any way from use of all or any part of the information in this document including, for the avoidance of doubt, direct or indirect or consequential loss or damage (including lost profits).
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication.
In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
Unless otherwise stated, Hybridan LLP owns the intellectual property rights and any other rights in this document. This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
